Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)

Terminated

Conditions: Breast Cancer
Tobacco Dependence

Interventions: Drug: placebo
Drug: varenicline

First Posted Date: 2012-02-14

Last Posted Date: 2015-12-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 7

Registration Number: NCT01532232

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: Afatinib and Paclitaxel

First Posted Date: 2012-02-01

Last Posted Date: 2023-11-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 42

Registration Number: NCT01522768

Locations: 🇺🇸
Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 6 locations

Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study

Active, not recruiting

Conditions: Breast Cancer
Rare Cancer

Interventions: Behavioral: AIM materials and assessments

First Posted Date: 2012-01-25

Last Posted Date: 2024-07-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 252

Registration Number: NCT01517945

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2

Completed

Conditions: Hodgkin's Lymphoma

Interventions: Drug: Brentuximab Vedotin (SGN-35)

First Posted Date: 2012-01-11

Last Posted Date: 2024-03-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 46

Registration Number: NCT01508312

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

International Travel Patterns and Health Preparations of Hematopoietic Stem Cell Transplant Recipients at Memorial Sloan-Kettering Cancer Center

Completed

Conditions: Hematopoietic Stem Cell Transplant

Interventions: Behavioral: questionnaire

First Posted Date: 2012-01-05

Last Posted Date: 2013-07-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 519

Registration Number: NCT01504152

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer

Phase 1

Completed

Conditions: Invasive Adenocarcinoma of the Breast
Breast Cancer

Interventions: Biological: Ipilimumab
Procedure: Cryoablation

First Posted Date: 2011-12-30

Last Posted Date: 2016-01-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 19

Registration Number: NCT01502592

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Examinations of Tissue from Ablated Malignant Liver Metastases As Predictors of Outcome

Not Applicable

Active, not recruiting

Conditions: Liver Cancer

Interventions: Other: CT guided percutaneous ablation

First Posted Date: 2011-12-19

Last Posted Date: 2024-10-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 150

Registration Number: NCT01494324

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

Phase 2

Completed

Conditions: Sarcoma
Neuroblastoma

Interventions: Drug: Cyclophosphamide, Topotecan, and Bevacizumab

First Posted Date: 2011-12-15

Last Posted Date: 2019-10-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT01492673

Locations: 🇨🇦
Alberta Children'S Hospital, Calgary, Alberta, Canada
🇺🇸
Phoenix Children'S Hospital, Phoenix, Arizona, United States
🇺🇸
University of Colorado Health Sciences Center and The Children's Hospital, Denver, Colorado, United States

and more 4 locations

Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Procedure: Roux-en-Y pouch reconstruction (RYP)
Procedure: conventional Roux-en-Y reconstruction (RYC)

First Posted Date: 2011-12-14

Last Posted Date: 2013-08-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT01491698

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Patient Factors Impacting Adherence to Oral Chemotherapy

Completed

Conditions: Breast Cancer
Gastrointestinal Cancer

Interventions: Behavioral: questionnaire and interview

First Posted Date: 2011-12-07

Last Posted Date: 2016-11-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 79

Registration Number: NCT01487343

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy